The global Botanical Plant Derived Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics, it is expected to be 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.
Market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for the development of pharmaceutical manufacturing segments, and rise in R&D activities for drugs. However, the industry faces challenges such as stringent regulations, high costs of research and development, and patent expirations.
This report provides a comprehensive analysis of the global Botanical Plant Derived Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.
Segmentation by Type
- Pill
- Tablet
- Capsule
Segmentation by Application
- Pharmacy
- Clinic Center
- Others
Market by Region
- Americas
- APAC
- Europe
- Middle East & Africa
Company's Coverage
- Abbott Laboratories
- Eli Lilly
- Medigene
- Pfizer
- Lupin
- Johnson & Johnson
- Ranbaxy Laboratories
- Novartis International AG
- GlaxoSmithKline
- Leo Pharma
Key Questions Addressed in this Report
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market